BIT.BIO
28.10.2021 10:25:07 CEST | Business Wire | Press release
Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will provide important guidance as bit.bio scales their proprietary synthetic biology cell programming technology platform, creating products and solutions based on human cells that can transform healthcare from basic research and drug discovery to next generation cell based therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005473/en/
Hermann Hauser will be the chair of the board. He brings valuable experience in creating entire new industries and markets through groundbreaking technologies with his experience as co-founder of Arm Ltd. holdings, a world leading UK computer chip company. As an early investor of Solexa (now Illumina), Dr. Hauser laid the foundation for the ongoing synthetic biology revolution with technologies to read the human genome. He is also a key member of the Cambridge science and technology community, as well as a trusted innovation advisor of the UK government. Dr. Hauser is a fellow of the Royal Society, KBE and co-founder of the venture capital firm Amadeus Capital Partners.
Hermann Hauser said:
“I believe bit.bio is well positioned to become one of the defining companies in the synthetic biology field, and I am very excited to take the position of chair of the board. I see world changing potential in their technology and look forward to bringing my experience and expertise to the leadership team. I want to see bit.bio grow into an iconic Cambridge company, creating jobs and new industries, and most importantly, bringing the next generation of medicines to patients.”
Sir Gregory Winter is a Nobel prize winning scientist who invented technologies for making therapeutic monoclonal antibodies, and was directly involved in their industrial development, notably through the start up company Cambridge Antibody Technology Ltd. His inventions underpin many of the therapeutic antibodies in development and on the market, including blockbuster drugs such as Humira, Herceptin, Avastin and Keytruda. More recently, through Bicycle Therapeutics, he has been helping to develop another invention - the use of bicyclic peptides as a platform for novel therapeutics.
Sir Gregory Winter said:
“I think we are still in the foothills when it comes to the use of human cells for therapeutic applications, and I am excited to join bit.bio on their journey to the peaks. With access to potentially unlimited numbers of human cells at defined states of differentiation, we could do so much more for patients - whether researching difficult to treat, complex diseases, screening potential drugs on human cells, or developing precision cell therapies at an affordable cost. And the opti-ox technology seems to offer a realistic path to scale those peaks.”
Alan S. Roemer will bring his entrepreneurial expertise from the biotechnology sector to bit.bio. As a life sciences executive and board director, he will offer meaningful capital markets and operational business building experience to ensure that bit.bio is well-financed and well-positioned to scale. Mr. Roemer has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, and consummated five IPOs. He was a founding leadership team member of Pharmasset (acquired by Gilead Sciences for $11 billion ) and Roivant Sciences, a company developing innovative medicines through a novel form of industrial organisation in R&D. His experience at Roivant is particularly relevant to bit.bio’s strategy to build its cell coding technology opti-ox into multiple verticals where human cells are applied to research, drug discovery and cell therapies. In addition to serving as a member of the board, Mr. Roemer will chair the audit and compensation committees.
Alan Roemer said:
"bit.bio is at that exciting stage of growth and evolution that I have been through several times before. It fuels my entrepreneurial spirit with the ‘fun factor’ of company expansion and cultural impact. I am excited to help the leadership team ‘see around corners’ using my experience from my other high-growth companies. Most importantly, I want to provide meaningful guidance to finance and scale the business, exploit the full potential of bit.bio’s core technology and have the potential to positively impact patients' lives.”
Mark Kotter, founder and CEO of bit.bio said:
“I’m humbled to be bringing together three world leaders in science, entrepreneurship and industry making for the board of bit.bio. The expertise and experience our new board will bring to the company will give our technology the best chance to transform healthcare for every patient, everywhere.”
- ENDS -
About bit.bio
Accelerated biomedical research, new generations of cures, increased global sustainability. These are in reach when biology transitions to engineering.
At bit.bio, we work relentlessly to achieve this goal. We combine the concepts of coding and biology to provide human cells for research, drug discovery, and a new generation of medicines.
For more information visit bit.bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces closing of initial public offering2.7.2026 20:35:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the closing of its initial public offering of an aggregate of 57,971,015 of its ordinary shares, at an initial public offering price of $29.00 per share. The offering consisted of 34,398,640 shares sold by Bending Spoons and 23,572,375 shares sold by certain selling shareholders (the “Selling Shareholders”). The gross proceeds from the offering to Bending Spoons, before deducting underwriting discounts and commissions and other offering expenses, was approximately $953,917,285.50. Bending Spoons did not receive any proceeds from the sale of shares by the Selling Shareholders. Bending Spoons’ ordinary shares began trading on the Nasdaq Global Select Market on July 1, 2026 under the ticker symbol “BSP”. Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP
Strategic Partnership Between Record Asset Management and Admicasa2.7.2026 19:00:00 CEST | Press release
RAM Swiss Holding AG announces a strategic partnership with Admicasa Holding AG (Admicasa). RAM Swiss Holding AG is a subsidiary of LSE-listed Record Financial Group (Record) and part of the Record Asset Management (RAM) group of companies. The partnership is a milestone in the growth of Admicasa and marks an important step in the continued expansion of Record’s private markets platform. Subject to regulatory approval, the agreement, signed on 1st July 2026, provides RAM Swiss Holding AG with a 50% participation in the Admicasa Fondsleitung AG, part of Admicasa, and establishes a long-term partnership to develop investment opportunities in the Swiss and Global real estate market with a plan to expand into other asset classes in the medium term. RAM is the European asset management arm of Record, the LSE-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 16:47:00 CEST | Press release
IQM begins trading on Nasdaq Global Select Market under the ticker symbol “IQMX” Company enters next phase of growth as a publicly traded leader in full-stack superconducting quantum computing IQM maintains a strong pro forma cash position of EUR 337 million IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quan
GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio2.7.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced today the launch of its new GD24CL series I²C EEPROM. The series delivers outstanding performance, comprehensive security protection mechanisms, and excellent reliability that addresses the stringent requirements for stable and long-term storage of critical configuration data. These offered features will benefit applications in industrial, energy, Internet-of-Things (IoT), data centers, and networking. As GigaDevice’s first EEPROM product series, the launch further enhances the company’s non-volatile memory portfolio and provides customers with more dynamic storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702394554/en/ GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio. The GD24CL series is designed with high
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom